John Wijdenes

12.0k citations

188 papers · 9.8k indexed · 1 hit paper · h-index 55

Impact in

Immunology top 0.2%
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
Hematology top 0.5%
- Multiple Myeloma Research and Treatments

Papers in

Immunology 97
- T-cell and B-cell Immunology 33
- Immune Cell Function and Interaction 32
- Immunotherapy and Immune Responses 26
- Immune Response and Inflammation 18
- Toxin Mechanisms and Immunotoxins 16
Hematology 34
- Multiple Myeloma Research and Treatments 20

Co-authors: Bernard Klein E Racadot L Aarden Pierre Galanaud L C Boeije Régis Bataille R J Smeenk Jorge Alcocer‐Varela
Journals: Blood (17 papers)The Journal of Immunology (10 papers)European Journal of Immunology (9 papers)Cytokine (6 papers)Journal of Immunological Methods (6 papers)
Partner nations: France Netherlands Germany

In The Last Decade

John Wijdenes

186 papers receiving 9.4k citations

Hit Papers

align trajectories log scale

Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. 1995 · 585 citations

Peers

Countries citing papers authored by John Wijdenes

Since Specialization

Citations

This map shows the geographic impact of John Wijdenes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Wijdenes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Wijdenes more than expected).

Fields of papers citing papers by John Wijdenes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Wijdenes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Wijdenes. The network helps show where John Wijdenes may publish in the future.

Co-authors

The 25 scholars most cited alongside John Wijdenes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Wijdenes Line = papers co-authored together John Wijdenes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Large scale preparation of human MHC class II+ integrin β1+ Tregs Journal of Immunological Methods ·So Yool Yoo, Urooj Raza Khan, Magdalena Lange, Martin Lenter, Kaitlin Roetcisoender, John Wijdenes, Helmut Jonuleit, Christian Becker	2010	2
2	Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function Blood ·Jan Kubach, Petra Lutter, Tobias Bopp, Sabine Stoll, Christian Becker, Eva N. Huter, Christoph Richter, Annette Gautero-Watzema, Tobias Warger, Jürgen Knop, Stefan Müllner, John Wijdenes, Hansjörg Schild, Edgar Schmitt, Helmut Jonuleit	2007	161
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human Monocytes: Evidence for Ectodomain Shedding of the Cell Surface GM-CSF Receptor α Subunit The Journal of Immunology ·S. Rahm, Ngbolua Koto-Te-Nyiwa, Bijoy K. Sinha, O F Ehrentheil, Paul Beaudry, Elif Dil, G. Gregory Neely, Emmanuel Claret, John Wijdenes, Christopher B. Brown	2002	18
4	SECRETION OF IL-6, IL-11 AND LIF BY HUMAN CARDIOMYOCYTES IN PRIMARY CULTURE Cytokine ·十六銀行香港駐在員事務所, Pierre Corbi, Josy Froger, Adriana Delwail, John Wijdenes, Hugues Gascan, Daniel Potreau, Jean‐Claude Lecron	2002	82
5	Circulating Concentrations of Soluble Interleukin 6 Receptors gp80 and gp130 in Chronic Renal Failure and Effects ofRenal Replacement Therapy American Journal of Nephrology ·Johan Frieling, Henk W. van Hamersvelt, John Wijdenes, Thijs Hendriks, Robert W. Sauerwein, Cees J. van der Linden	1999	9
6	Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma International Journal of Cancer ·Jean‐Yves Blay, Jean‐François Rossi, John Wijdenes, Christine Ménétrier‐Caux, Zhiqiang 志强 Zhang 张, Sylvie Négrier, Thierry Philip, Marie Favrot	1997	16
7	Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma International Journal of Cancer ·Jean‐Yves Blay, Jean‐François Rossi, John Wijdenes, Christine Ménétrier‐Caux, Zhiqiang 志强 Zhang 张, Sylvie Négrier, Thierry Philip, Marie Favrot	1997	184
8	Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family. PubMed ·Félix A. Montero‐Julian, Hervé Brailly, (unknown), I Joyeux, Thierry Dorval, Véronique Mosseri, Kiyoshi Yasukawa, John Wijdenes, Alexander P. Adler, I. Gorin, Wolf H. Fridman, Éric Tartour	1997	33
9	Reconstitution of two isoforms of the human interleukin‐11 receptor and comparison of their functional properties FEBS Letters ·B. Lebeau, Cassiana Hygino Machado, John Wijdenes, Gerhard Müller‐Newen, Heike Dahmen, Michel Chérel, Peter C. Heinrich, Hervé Brailly, Marie‐Martine Hallet, Anne Godard, Stéphane Minvielle, Yannick Jacques	1997	29
10	In VivoInfusion of Anti-LFA-1 and Anti-CD2 Antibodies Prevents Graft Failure After HLA Partially Incompatible Bone Marrow Transplantation in Children with High Risk Acute Lymphoblastic Leukaemia Leukemia & lymphoma ·Marina Cavazzana, Nada Jabado, Pierre Bordigoni, Gérard Michel, Élie Haddad, Françoise Méchinaud, Judith Landman‐Parker, Patel Kunjankumar F, E Plouvier, André Baruchel, JL Stéphan, G Souillet, E Vilmer, John Wijdenes, F Le Deist, Alain Fischer	1997	5
11	Molecular Modeling-guided Mutagenesis of the Extracellular Part of gp130 Leads to the Identification of Contact Sites in the Interleukin-6 (IL-6)·IL-6 receptor·gp130 Complex Journal of Biological Chemistry ·Ursula Horsten, Gerhard Müller‐Newen, Claudia Gerhartz, Axel Wollmer, John Wijdenes, Peter C. Heinrich, Joachim Grötzinger	1997	65
12	Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing RWTH Publications (RWTH Aachen) ·Radovan Keul, S Matern, 张沁莹, M. Hart, Just P. J. Brakenhoff, Ulrike Hemmann, Peter C. Heinrich, Gerhard Müller‐Newen, Werner Müller‐Esterl, John Wijdenes	1996	8
13	Treatment of severe Crohn's disease with anti‐CD4 monoclonal antibody Alimentary Pharmacology & Therapeutics ·V. Canva-Delcambre, Serge Jacquot, Éric Robinet, Marc Lémann, Christian Drouet, Myriam Labalette, J.P. Dessaint, Estefany Lema, Bingzhen Cao, R Modigliani, John Wijdenes, J. P. Révillard, J.F. Colombel	1996	26
14	Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. The Journal of Experimental Medicine ·Luis Llorente, Weiguo Zou, Yves Lévy, Yvonne Richaud‐Patín, John Wijdenes, Jorge Alcocer‐Varela, B Morel-Fourrier, J C Brouet, D Alarcón-Segovia, Pierre Galanaud, D Émilie	1995	440
15	Interleukin-6 Antibodies in Rheumatoid Arthritis Journal of Interferon Research ·John Wijdenes, E Racadot, Daniel Wendling	1994	10
16	Pharmacokinetics of Interleukin-6 During Therapy with Anti-Interleukin-6 Monoclonal Antibodies: Enhanced Clearance of Interleukin-6 by a Combination of Three Anti-Interleukin-6 Antibodies Journal of Interferon Research ·Félix A. Montero‐Julian, Emmanuel Gautherot, John Wijdenes, Bernard Klein, Hervé Brailly	1994	19
17	The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin Journal of Dermatological Science ·VM LOUREIRO, Jean‐François Nicolas, Kaettipong Kampreasart, Jean Kanitakis, Aïcha Demidem, Virgo Josua Sihotang, John Wijdenes, J Thivolet, Daniel Schmitt	1994	24
18	B-B10 (ANTI-CD25)-SAPORIN IMMUNOTOXIN—A POSSIBLE TOOL IN GRAFT-VERSUS-HOST DISEASE TREATMENT Transplantation ·Pier Luigi Tazzari, Andrea Bolognesi, Daniela de Totero, Stefano Pileri, Roberto Conte, John Wijdenes, Patrick Hervé, Marco R. Soria, Fiorenzo Stirpe, Marco Gobbi	1992	18
19	Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone Clinical Rheumatology ·Daniel Wendling, E Racadot, B Morel-Fourrier, John Wijdenes	1992	25
20	A monoclonal anti-IgE antibody against an epitope (amino acids 367-376) in the CH3 domain inhibits IgE binding to the low affinity IgE receptor (CD23). The Journal of Immunology ·Isabelle Chrétien, Birgit A. Helm, Phil Marsh, Eduardo A. Padlan, John Wijdenes, Jacques Banchereau	1988	36

About John Wijdenes

John Wijdenes is a scholar working on Immunology, Hematology, Immunology and Allergy, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 188 papers that have together received 9.8k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (49 papers), T-cell and B-cell Immunology (33 papers), Immune Cell Function and Interaction (32 papers), Cytokine Signaling Pathways and Interactions (29 papers), Immunotherapy and Immune Responses (26 papers), Multiple Myeloma Research and Treatments (20 papers), Immune Response and Inflammation (18 papers) and Toxin Mechanisms and Immunotoxins (16 papers). The work is most often cited by research in Immunology (5.0k citations), Hematology (1.8k citations), Oncology (3.0k citations), Rheumatology (1.4k citations) and Immunology and Allergy (563 citations). John Wijdenes has collaborated with scholars based in France, Netherlands and Germany. Frequent co-authors include Bernard Klein, E Racadot, L Aarden, Pierre Galanaud, L C Boeije, Régis Bataille, R J Smeenk, Jorge Alcocer‐Varela, Yvonne Richaud‐Patín and Jacques Banchereau. Their work appears in journals such as Blood, The Journal of Immunology, European Journal of Immunology, Cytokine and Journal of Immunological Methods.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact